Verge Genomics Announces Three-Year Collaboration With Lilly to Discover and Develop Novel Treatments Using Its AI-Driven All-in-Human Platform

SAN FRANCISCO--(BUSINESS WIRE)--Verge Genomics, a biotech company that has created an industry leading all-in-human, artificial-intelligence-powered drug discovery and development platform focused on therapies for serious genetic diseases, today announced a three-year collaboration with Eli Lilly and Company to research and develop novel therapies for the treatment of amyotrophic lateral sclerosis...

Click to view original post